Annual report pursuant to Section 13 and 15(d)

Supplemental Cash Flow Information (Details)

v2.4.0.8
Supplemental Cash Flow Information (Details) (USD $)
In Thousands, unless otherwise specified
12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2011
Summary of supplemental cash flow information      
Interest paid $ 3,407 $ 945 $ 726
Income taxes paid, net 1,321 575 338
Shares issued upon the conversion of:      
Series D Preferred Stock 24,386 0 1,742
3.00% convertible senior notes   0 0
Common Stock warrants, net exercised 815 7 1,155
PROLOR [Member]
     
Issuance of capital stock to acquire:      
Issuance of common stock 586,643 0 0
OPKO Diagnostics [Member]
     
Issuance of capital stock to acquire:      
Issuance of common stock 0 0 22,452
FineTech [Member]
     
Issuance of capital stock to acquire:      
Issuance of common stock 0 0 17,717
Farmadiet [Member]
     
Issuance of capital stock to acquire:      
Issuance of common stock 4,435 805 0
OURLab [Member]
     
Issuance of capital stock to acquire:      
Issuance of common stock 0 32,888 0
OPKO Brazil [Member]
     
Issuance of capital stock to acquire:      
Issuance of common stock 435 0 0
Cytochroma [Member]
     
Issuance of capital stock to acquire:      
Issuance of common stock 146,902 0 0
Rxi Pharmaceuticals Corporation [Member]
     
Summary of supplemental cash flow information      
Revenue related to sale of intellectual property $ 12,500 $ 0 $ 0